Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TC11 is an optimized sulfonamide-indolinone hybrid, derived from molecular hybridization of derivative 5d with the polar tail of sunitinib. It exhibits superior antiproliferative activity against breast cancer cells, particularly those dependent on mitochondrial oxidative phosphorylation (OXPHOS). TC11 functions by significantly reducing and impairing mitochondrial respiration and mitochondria-dependent reactive oxygen species (ROS) production in breast cancer cells. This leads to G0/G1 cell cycle arrest and apoptosis in MCF7 breast cancer cells. Notably, TC11 demonstrates selectivity, as anticancer doses do not elicit cytotoxic effects on normal cardiomyoblasts and hepatocytes, highlighting its therapeutic potential for targeting metabolic vulnerabilities in OXPHOS-dependent breast cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TC11.